MannKind stock weighs 43 percent revenue growth against losses

Published on 10/05/2026 at 18:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MannKind stock traded at USD 3.79 on October 5, 2026, with a USD 1.2 billion market cap. Its latest quarter brought USD 109.4 million in revenue and a USD 19.0 million loss.

MNKD, US56400P7069, Illustration mit AI erstellt.

MannKind stock (ISIN US56400P7069) was trading at USD 3.79 on Nasdaq on October 5, 2026, down 0.34 percent from the prior close. The biotechnology company enters the final quarter with Q2 revenue growth, a deeper quarterly loss and a new inhaled GLP-1 licensing opportunity.

Revenue reaches USD 109.4 million

MannKind reported USD 109.4 million in Q2 2026 revenue, up 43 percent from the comparable period, according to Trefis on October 3, 2026. The figure gives the commercial portfolio greater scale, but revenue growth has not yet translated into quarterly profitability.

GAAP net loss was USD 19.0 million in Q2 2026, compared with net income of USD 0.7 million in the year-earlier quarter, the same Trefis report states. MannKind's structured financial data also show diluted EPS of negative USD 0.06 and a gross profit margin of 73 percent for Q2 2026.

Rose Pharma adds a pipeline option

On September 9, 2026, MannKind announced a worldwide licensing and collaboration agreement with Rose Pharma for ROSE-010 Technosphere, an investigational inhaled GLP-1 for weight management. MannKind will receive an equity interest, potential royalties and board representation while supporting development through completion of a Phase 1b study.

The arrangement shifts later clinical, regulatory and commercial responsibility to Rose Pharma, according to the company release. For MannKind, the potential value is tied to an early-stage program rather than near-term product revenue, making commercial execution in its existing portfolio the more immediate financial test.

Analyst target stays above USD 8

MarketBeat lists a Moderate Buy consensus for MannKind based on 10 analysts, with an average price target of USD 8.34, a high target of USD 13.00 and a low target of USD 4.75. The target spread highlights the different views around the company's path from revenue growth to durable earnings.

Stock trades below its yearly high

MannKind stock was trading at USD 3.79 on Nasdaq on October 5, 2026, at 12:46 p.m. ET. The session range was USD 3.70 to USD 3.85, the 52-week range was USD 2.23 to USD 6.51, market capitalization was USD 1.2 billion and volume was 816,714 shares.